Top in endocrinology: Intermittent fasting, triple therapy for diabetes
Click Here to Manage Email Alerts
Continuous glucose monitoring can help people with well-managed diabetes safely try intermittent fasting, according to experts. It was the top story in endocrinology last week.
Another top story was about a presentation at the Heart in Diabetes meeting that concluded triple combination therapy with an SGLT2 inhibitor, GLP-1 receptor agonist and thiazolidinedione pioglitazone could be the optimal solution for cardiovascular and renal protection in patients with type 2 diabetes.
Read these and more top stories in endocrinology below:
Safe intermittent fasting possible for people with diabetes
People with well-managed diabetes who wish to try intermittent fasting for weight loss or other reasons can do so safely with careful attention to glucose levels, particularly with continuous glucose monitoring, according to two speakers. Read more.
Triple combination therapy may be optimal for CV protection in type 2 diabetes
Triple therapy combining an SGLT2 inhibitor, a GLP-1 receptor agonist and the thiazolidinedione pioglitazone could serve as an optimal solution for cardiovascular and renal protection in type 2 diabetes, according to a speaker. Read more.
FDA: Amputation risk boxed warning removed from canagliflozin
The FDA has removed from the prescribing information for the SGLT2 inhibitor canagliflozin (Invokana, Invokamet and Invokamet XR; Janssen) a caution about increased leg and foot amputations among adults with type 2 diabetes taking the drug, according to a press release. Read more.
Nearly 40% of postmenopausal women may have depressive symptoms
Risk factors for postmenopausal depressive symptoms included being unpartnered, consuming alcohol, requiring chronic medication and having many children, according to results of a study from researchers in Turkey. Read more.
Hyperglycemia, high or low BMI risk factors for COVID-19 death in people with diabetes
Hyperglycemia, underweight or obesity and previous cardiovascular and renal complications could put people with diabetes at higher risk for COVID-19-related death, according to a study published in The Lancet Diabetes Endocrinology. Read more.